Study Title

novartis

Phase I, Open-label, Multicenter Study to Evaluate the Imaging Performance, Safety, Biodistribution and Dosimetry of [68Ga]-FF58 in Adult Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Study Details

Description:

This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme (GBM), breast cancer (BC) that has metastasized to the brain, gastroesophageal adenocarcinoma (GEA) or pancreatic ductal adenocarcinoma (PDAC) expected to overexpress alpha-v beta 3 (αvβ3) and alpha-v beta 5 (αvβ5) integrins.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682

Government Study Link:

NCT04712721 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Novartis Pharmaceuticals for more information.

1-888-669-6682

novartis.email@novartis.com